We are live on
!
Find out more
OCA
Octagon Capital Advisors Portfolio holdings
AUM
$904M
1-Year Est. Return
737.04%
This Fund
S&P 500
This Quarter
Est. Return
+21.23%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$719M
AUM Growth
+$23.6M
(+3.4%)
Cap. Flow
-$72.6M
Cap. Flow
% of AUM
-10.1%
Top 10 Holdings %
Top 10 Hldgs %
74.6%
Holding
48
New
12
Increased
6
Reduced
8
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vir Biotechnology
VIR
|
+$16.3M |
| 2 |
OKUR
OnKure Therapeutics
OKUR
|
+$15.7M |
| 3 |
Disc Medicine
IRON
|
+$14.7M |
| 4 |
ETNB
89bio
ETNB
|
+$11.7M |
| 5 |
Insmed
INSM
|
+$6.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$59.1M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$54.5M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$8.59M |
| 4 |
Viridian Therapeutics
VRDN
|
+$6.72M |
| 5 |
Vera Therapeutics
VERA
|
+$6.55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
| $239M | 33.19% |
2,618,300
-631,700
| -19% | -$54.5M |
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $52.2M | 7.26% |
2,468,000
| – | – |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $50.1M | 6.96% |
4,570,918
| – | – |
|
4
Arcus Biosciences
RCUS
$3.44B
| $40M | 5.56% |
1,968,000
-204,000
| -9% | -$3.88M |
|
5
Roivant Sciences
ROIV
$24.8B
| $39.4M | 5.48% |
3,904,000
| – | – |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $27.1M | 3.77% |
750,000
| – | – |
|
7
Celldex Therapeutics
CLDX
$2.77B
| $25.8M | 3.59% |
759,898
| – | – |
|
|
8
Viridian Therapeutics
VRDN
$1.99B
| $22M | 3.06% |
923,000
-262,000
| -22% | -$6.72M |
|
9
BridgeBio Pharma
BBIO
$15.9B
| $21M | 2.92% |
1,219,200
-118,960
| -9% | -$1.79M |
|
|
ETNB
10
DELISTED
89bio
ETNB
| $20.2M | 2.81% |
1,066,784
+666,784
| +167% | +$11.7M |
|
|
11
Disc Medicine
IRON
$2.91B
| $18.4M | 2.56% |
+415,000
| New | +$14.7M |
|
|
12
Vir Biotechnology
VIR
$1.59B
| $15.9M | 2.22% |
+650,100
| New | +$16.3M |
|
|
OKUR
13
OnKure Therapeutics
OKUR
$170M
| $15.5M | 2.16% |
236,859
+194,859
| +464% | +$15.7M |
|
14
Tandem Diabetes Care
TNDM
$1.17B
| $11.7M | 1.62% |
474,929
| – | – |
|
|
JBIO
15
Jade Biosciences
JBIO
$1.27B
| $10.7M | 1.48% |
17,763
| – | – |
|
|
ITOS
16
DELISTED
iTeos Therapeutics
ITOS
| $7.89M | 1.1% |
596,000
| – | – |
|
17
Dyne Therapeutics
DYN
$3.92B
| $7.8M | 1.08% |
692,945
| – | – |
|
|
18
Insmed
INSM
$23.5B
| $7.74M | 1.08% |
+367,000
| New | +$6.96M |
|
|
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
| $7.71M | 1.07% |
750,000
-452,000
| -38% | -$4.08M |
|
20
Travere Therapeutics
TVTX
$5.27B
| $7.6M | 1.06% |
495,000
| – | – |
|
21
Geron
GERN
$924M
| $7.31M | 1.02% |
2,278,000
| – | – |
|
22
Xilio Therapeutics
XLO
$58.4M
| $6.35M | 0.88% |
173,214
| – | – |
|
23
AN2 Therapeutics
ANTX
$169M
| $6.13M | 0.85% |
+720,900
| New | +$5.18M |
|
24
Jasper Therapeutics
JSPR
$24.8M
| $6.12M | 0.85% |
446,811
-191,439
| -30% | -$2.84M |
|
25
Viking Therapeutics
VKTX
$4.31B
| $6.08M | 0.85% |
375,000
| – | – |
|
Similar funds
AIC
AOWM
SWM
EI
PIP
PSCM
EWM
PC
Octagon Capital Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, Octagon Capital Advisors held 48 positions worth $719M, up 3.4% from $695M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Octagon Capital Advisors withdrew a net $72.6M in Q2 2023, closing 7 positions and reducing 8 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $59.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
Against the trend, Octagon Capital Advisors opened a new position in Vir Biotechnology worth $15.9M.
- Octagon Capital Advisors's largest Q2 2023 buy was Vir Biotechnology: 650,100 shares worth $15.9M.
- Octagon Capital Advisors added most to OnKure Therapeutics in Q2 2023, an estimated $15.7M increase.
- Octagon Capital Advisors's biggest Q2 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $54.5M.
- Octagon Capital Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $59.1M.
- Octagon Capital Advisors's ten largest holdings make up 75% of its $719M portfolio in Q2 2023.
- Octagon Capital Advisors opened 12 new positions and closed 7 in Q2 2023.
- Octagon Capital Advisors's portfolio value rose 3.4% quarter-over-quarter to $719M.
Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.